Members of our Kidney Tumor Program also oversee laboratory and clinical research designed to improve understanding and treatment of childhood kidney tumors. Because Dana-Farber/Boston Children’s Cancer and Blood Disorders Center is the regional Phase I center for the Children's Oncology Group, a collaborative research organization dedicated to improving the treatment of childhood cancers, our center offers treatments unavailable at other regional institutions. We also collaborate with other pediatric centers across the country to offer unique treatment options.
Identifying the best treatment for Wilms tumor
Major advancements have occurred in treatment of Wilms tumor over the last two decades, primarily because of studies by the National Wilms Tumor Study Group, of which Dana-Farber/Boston Children's was a member. These studies have rigorously compared treatment regimens and helped define the right treatment for each stage and type of Wilms tumor. In one large study, it was shown for low stage Wilms tumor that briefer courses of therapy were safer and as effective as longer courses.
Risk-stratifying treatment of children with bilateral tumors
The traditional treatment for pediatric kidney tumors is a two-step process: Surgeons remove as much of the tumor as possible, then oncologists use chemotherapy to kill remaining cancerous cells. If the tumor is bilateral (appearing in both kidneys), chemotherapy is sometimes also used before surgery to reduce the size of the tumor. Our researchers are investigating the use of continuous pathological review throughout treatment to evaluate the best therapeutic approach for bilateral pediatric kidney tumors.
Searching for markers
Researchers are conducting studies to better understand how to diagnose and treat renal (kidney) tumors. For example, researchers at our center are investigating whether kidney tumors emit markers in a child’s urine. If discovered, these markers could be used to screen for early recurrence of relapsed cancers. They may also help clinicians screen types of tumors up front, so treatments are personalized to the exact makeup of a child’s tumor.
Our researchers are also global leaders in the basic and translational study of rhabdoid tumors, including malignant rhabdoid tumors and atypical teratoid/rhabdoid tumors. Their goal: to understand the biological basis of rhabdoid tumors, including the role(s) of mutations in the gene, SMARCB1, and to develop more effective treatment methods for children with these tumors.
